ZEPBOUND 12.5mg/0.5ml (Tirzepatide Vials) 12.5mg/0.5ml

ZEPBOUND is a dual GIP and GLP-1 receptor agonist used in the management of obesity and related conditions. It is designed to aid in weight loss and improve obesity-related health outcomes.

• Obesity: Helps adults with obesity to lose excess body weight and keep the weight off.
• Overweight with weight-related comorbidities: Assists overweight adults with conditions such as type 2 diabetes, hypertension, or dyslipidemia to manage their weight.
• Moderate-to-severe obstructive sleep apnea (OSA) and obesity: Improves OSA symptoms in adults with obesity.

• Tirzepatide, the active ingredient in ZEPBOUND, works as an agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action enhances insulin secretion, reduces glucagon levels, slows gastric emptying, and decreases appetite, leading to improved glycemic control and weight loss.

ZEPBOUND may cause various side effects, ranging from common to serious. Common side effects typically include gastrointestinal symptoms, while serious side effects are rare but can be severe.

Common Side Effects

• Nausea: A frequent side effect that may occur during treatment.
• Diarrhea: Another common gastrointestinal symptom.
• Vomiting: May occur, particularly at the start of treatment.
• Constipation: Can be experienced by some patients.
• Injection site reactions: Redness, swelling, or itching at the injection site.
• Fatigue: A general feeling of tiredness or lack of energy.

Serious or Rare Side Effects

• Thyroid tumors: ZEPBOUND may cause tumors in the thyroid, including thyroid cancer. Symptoms include a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath.
• Pancreatitis: Inflammation of the pancreas, which can be severe and requires immediate medical attention.
• Hypoglycemia: Low blood sugar levels, especially when used with other diabetes medications.
• Kidney problems: May include kidney failure or worsening of existing kidney disease.
• Allergic reactions: Severe allergic reactions, though rare, can occur and require immediate medical attention.

ZEPBOUND should be used with caution and under the supervision of a healthcare provider. Certain precautions and warnings should be observed to ensure safe use.

• Prescription use: ZEPBOUND is a prescription medication and should only be used as directed by a healthcare provider.
• Thyroid monitoring: Regular monitoring for thyroid tumors is recommended, especially in patients with a history of thyroid disease.
• Pancreatitis risk: Patients should be monitored for signs of pancreatitis, such as severe abdominal pain, nausea, and vomiting.
• Hypoglycemia risk: Caution is advised when using ZEPBOUND with other diabetes medications to avoid low blood sugar levels.
• Kidney function: Regular monitoring of kidney function is recommended, particularly in patients with existing kidney disease.
• Allergic reactions: Patients should be aware of the signs of an allergic reaction and seek immediate medical attention if they occur.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

ZEPBOUND may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects. It is important to inform your healthcare provider about all medications you are taking.

Major Interactions (Avoid)

• Other tirzepatide-containing products: Avoid using ZEPBOUND with other tirzepatide-containing products to prevent overdose and adverse effects.
• GLP-1 receptor agonist medicines: Avoid concurrent use with other GLP-1 receptor agonist medicines to prevent overlapping side effects and interactions.

Moderate Interactions (Monitor Closely)

• Insulin: Monitor blood sugar levels closely when using ZEPBOUND with insulin to avoid hypoglycemia.
• Sulfonylureas: Monitor blood sugar levels closely to avoid hypoglycemia.
• Other diabetes medications: Monitor blood sugar levels and adjust doses as needed to avoid hypoglycemia.
• Medications that affect gastric emptying: Monitor for changes in the effectiveness of ZEPBOUND and other medications.